focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment to Scientific Advisory Board

3 Sep 2014 07:00

RNS Number : 6680Q
Collagen Solutions PLC
03 September 2014
 



Collagen Solutions Plc

(the "Company" or the "Group")

 

Mr Tom Hyland joins Collagen Solutions Scientific Advisory Board.

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to welcome Mr Tom Hyland as scientific adviser to the company.

 

Mr Hyland has a wealth of experience in the field of collagen chemistry and the development, manufacturing, validation and engineering requirements of collagen-based medical devices. He is a recognised expert in the field as a six sigma black belt, and has played a major role in bringing a number of highly successful collagen-based products to market.

 

Tom has worked with an impressive list of global life science companies, including Johnson and Johnson Wound Management where he was involved in the identification and commercialisation of a series of products which now have global sales exceeding £50m per annum. He was also employed at Microsulis, Intercell, Alere and Invitrogen, in a range of senior operational roles in the areas of Drugs, Diagnostics & Interventional Devices, manufacture scale up and production technology.

 

Such expertise is now essential as Collagen Solutions starts to develop its own proprietary products, including the technology of Professor Robert Brown at UCL that was recently licensed. Tom will be working closely with Professor Brown and the management team to identify and oversee the manufacture and development of novel collagen-based products for Collagen Solutions to commercialise.

 

Dr Stewart White, Chief Executive Officer of Collagen Solutions, said: "Tom has over 25 years of identifying and manufacturing collagen devices, diagnostics and biological products which is an ideal profile for us as we capture a greater proportion of the value chain and develop our own range of proprietary collagen products. I am delighted to welcome Tom to our scientific advisory board where he will be able to identify and create the new generation of collagen products that will create shareholder value in this rapidly growing and exciting area of regenerative medicine. Tom's common sense approach, collagen engineering pedigree and operational capabilities will add real value to our business and help accelerate company growth and help deliver our strategy and realise our vision."

 

Mr Hyland is currently the General Manager of API Foils Europe in Livingston, has a Honours Degree in Chemistry and Chemical Engineering and a MBA from Herriot Watt University.

 

 

 

Enquiries:

 

Collagen Solutions Plc

 

David Evans, Chairman 

Tel: 07740 084 452

Stewart White, CEO

Tel: 0141 558 2008

 

 

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews / John Depasquale (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

Notes to Editors:

Six Sigma

Six Sigma is a business management strategy that was initially developed by Motorola in the 1980's, and now is used in many Fortune 500 companies. It is used primarily to identify and rectify errors and defects in a manufacturing or business process in order to increase efficiencies and output.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABLGDCRGGBGSD
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.